| Literature DB >> 31091754 |
Vanessa Oertzen-Hagemann1, Marius Kirmse2, Britta Eggers3, Kathy Pfeiffer4, Katrin Marcus5, Markus de Marées6, Petra Platen7.
Abstract
Evidence has shown that protein supplementation following resistance exercise training (RET) helps to further enhance muscle mass and strength. Studies have demonstrated that collagen peptides containing mostly non-essential amino acids increase fat-free mass (FFM) and strength in sarcopenic men. The aim of this study was to investigate whether collagen peptide supplementation in combination with RET influences the protein composition of skeletal muscle. Twenty-five young men (age: 24.2 ± 2.6 years, body mass (BM): 79.6 ± 5.6 kg, height: 185.0 ± 5.0 cm, fat mass (FM): 11.5% ± 3.4%) completed body composition and strength measurements and vastus lateralis biopsies were taken before and after a 12-week training intervention. In a double-blind, randomized design, subjects consumed either 15 g of specific collagen peptides (COL) or a non-caloric placebo (PLA) every day within 60 min after their training session. A full-body hypertrophy workout was completed three times per week and included four exercises using barbells. Muscle proteome analysis was performed by liquid chromatography tandem mass spectrometry (LC-MS/MS). BM and FFM increased significantly in COL compared with PLA, whereas no differences in FM were detected between the two groups. Both groups improved in strength levels, with a slightly higher increase in COL compared with PLA. In COL, 221 higher abundant proteins were identified. In contrast, only 44 proteins were of higher abundance in PLA. In contrast to PLA, the upregulated proteins in COL were mostly associated with the protein metabolism of the contractile fibers. In conclusion, the use of RET in combination with collagen peptide supplementation results in a more pronounced increase in BM, FFM, and muscle strength than RET alone. More proteins were upregulated in the COL intervention most of which were associated with contractile fibers.Entities:
Keywords: collagen hydrolysate; protein supplementation; proteome; proteomics; resistance exercise
Mesh:
Substances:
Year: 2019 PMID: 31091754 PMCID: PMC6566884 DOI: 10.3390/nu11051072
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
Figure 1Flow chart describing the experimental design. Pre- and post-testing consisted of three test days (TD1–3) separated by a 12-week intervention period with collagen or placebo supplementation each day and hypertrophy resistance training three days per week. MViC: Maximal voluntary isometric contraction; RM: Repetition Maximum.
Results for body mass (BM), fat mass (FM), fat free mass (FFM), the squat test (SQ), dead lift (DL), bench press (BP), rowing (R), and isometric strength testing (MViC) before and after the 12-week intervention period. Data are presented for the collagen and placebo groups (means ± SD) as a pre- and post-test comparison. Statistical significance for interactions as determined by ANOVA was considered as p ≤ 0.05, and the level of significance for the post-hoc t-tests was set at p ≤ 0.0125 after Bonferroni correction.
| Characteristic | Collagen Group ( | Placebo Group ( | Interaction | Post-Test Difference between Groups | ||
|---|---|---|---|---|---|---|
| Pre | Post | Pre | Post | |||
| BM (kg) | 81.4 ± 6.6 | 84.4 ± 6.3 * | 77.9 ± 4.1 | 79.4 ± 5.1 * | 0.035 | n.s. (0.039) |
| FM (kg) | 10.3 ± 3.6 | 10.9 ± 4.1 * | 8.4 ± 2.2 | 9.4 ± 2.4 * | n.s. (0.534) | - |
| FFM (kg) | 71.2 ± 5.7 | 73.8 ± 5.3 * | 69.6 ± 4.0 | 70.3 ± 4.3 * | 0.014 | n.s. (0.080) |
| SQ (kg) | 114.3 ± 20.2 | 140.8 ± 24.3 * | 108.7 ± 8.3 | 126.3 ± 13.9 * | n.s. (0.073) | n.s. (0.084) |
| DL (kg) | 131.7 ± 19.6 | 156.3 ± 21.2 * | 128.0 ± 15.6 | 143.9 ± 10.6 * | n.s. (0.234) | - |
| BP (kg) | 80.4 ± 14.0 | 94.4 ± 15.6 * | 84.4 ± 13.9 | 94.2 ± 10.2 * | n.s. (0.099) | n.s. (0.987) |
| R (kg) | 85.0 ± 11.3 | 98.3 ± 12.6 * | 91.2 ± 8.9 | 97.3 ± 8.1 * | 0.025 | n.s. (0.812) |
| MViC (nM) | 294.3 ± 56.3 | 323.6 ± 72.1 * | 260.7 ± 25.0 | 275.2 ± 31.3 * | n.s. (0.066) | n.s. (0.059) |
* significantly different to pre-test (post-hoc paired t-test with Bonferroni correction to p ≤ 0.0125). n.s. = not significant.
Differences (mean ± SD) in post-test values between the collagen (COL) group and placebo (PLA) group in body mass (BM), fat mass (FM), fat free mass (FFM), the squat test (SQ), dead lift (DL), bench press (BP), rowing (R), and isometric strength testing (MViC) before and after the 12-week intervention period. Unpaired t-tests were used to detect differences between both groups after the intervention (level of significance was set to p ≤ 0.05).
| Exercise | Collagen Group | Placebo Group | Unpaired |
|---|---|---|---|
| Delta | Delta | ||
| BM (kg) | 3.01 ± 2.01 | 1.50 ± 1.29 | 0.035 |
| FM (kg) | 0.58 ± 1.47 | 0.90 ± 1.09 | n.s. (0.534) |
| FFM (kg) | 2.56 ± 2.22 | 0.70 ± 1.14 | 0.014 |
| SQ (kg) | 26.5 ± 13.2 | 17.6 ± 9.9 | n.s. (0.073) |
| DL (kg) | 24.5 ± 19.1 | 15.9 ± 13.9 | n.s. (0.234) |
| BP (kg) | 14.0 ± 6.6 | 9.8 ± 5.5 | n.s. (0.099) |
| R (kg) | 13.3 ± 8.7 | 6.1 ± 5.8 | 0.025 |
| MViC (nM) | 29.4 ± 22.9 | 14.5 ± 14.3 | n.s. (0.066) |
n.s. = not significant.
Upregulated proteins in the collagen (COL) and placebo (PLA) group showing baseline differences before the intervention.
| UniProt | Gene Name | Protein Description | Fold Change (FC) | ||
|---|---|---|---|---|---|
| Collagen | Placebo | ||||
| Only upregulated in COL before 12 weeks | |||||
| - | - | - | |||
| Only upregulated in PLA before 12 weeks | |||||
| P10636 | MAPT | Microtubule-associated protein tau | - | 1.63 | |
| P02144 | MB | Myoglobin | - | 1.71 | |
| P09493 | TPM1 | Tropomyosin alpha-1 chain | - | 1.52 | |
Figure 2Venn diagrams showing different numbers of (a) significantly downregulated and (b) upregulated proteins in the placebo (blue) and collagen (green) groups after 12-week resistance exercise training and supplementation. The intersection represents proteins that were regulated in both groups.
Figure 3Gene Ontology (GO) analysis of proteins from the (a) intersection, (b) collagen group, and (c) placebo group after 12 weeks of resistance training and supplementation calculated by PANTHER. The false discovery rate (FDR) is marked with a dashed line at 0.10.
Figure 4Pie chart shows significantly overrepresented pathways in the collagen (COL) group after 12 weeks of resistance training and supplementation analyzed by PANTHER. Size of the different colored parts indicates number of assigned pathways.
Overrepresented pathways in the collagen (COL) group after 12 weeks of resistance training and supplementation. Main categories are shown with the number of annotated pathways and downstream pathways with the calculated fold enrichment and false discovery rate (FDR).
| Pathway | Number of Pathways | Fold Enrichment | FDR |
|---|---|---|---|
|
|
| ||
|
|
| ||
| PIP3 activates AKT signaling | 3.98 | 3.56 × 10−3 | |
| MAPK family signaling cascades | 5.22 | 7.42 × 10−6 | |
| MAPK6/MAPK4 signaling | 9.65 | 1.47 × 10−5 | |
| MAPK1/MAPK3 signaling | 6.09 | 1.63 × 10−6 | |
| RAF/MAP kinase cascade | 6.22 | 1.37 × 10−6 | |
| Regulation of RAS by GAPs | 12.63 | 2.48 × 10−6 | |
|
|
| ||
| MAP kinase activation | 7.57 | 7.58 × 10−3 | |
| Cytokine signaling in immune system | 3.71 | 7.00 × 10−7 | |
| Signaling by Interleukins | 4.25 | 2.51 × 10−6 | |
| Interleukin-1 family signaling | 7.66 | 8.30 × 10−6 | |
| Interleukin-1 signaling | 10.39 | 8.47 × 10−7 | |
| MAP3K8 (TPL2)-dependent MAPK1/3 activation | 17.89 | 9.74 × 10−3 | |
| Interleukin-12 family signaling | 6.70 | 3.23 × 10−2 | |
|
|
| ||
| Translation | 3.91 | 1.13 × 10−3 | |
| Eukaryotic translation elongation | 9.14 | 2.11 × 10−5 | |
| Eukaryotic translation initiation | 6.42 | 7.41 × 10−4 | |
| Eukaryotic translation termination | 6.16 | 6.39 × 10−3 | |
| Protein folding | 7.63 | 2.41 × 10−4 | |
| Post-chaperonin tubulin folding pathway | 17.35 | 1.79 × 10−3 | |
| Cooperation of prefoldin and TriC/CCT in actin and tubulin folding | 17.89 | 3.86 × 10−5 | |
| Formation of tubulin folding intermediates by CCT/TriC | 19.09 | 1.90 × 10−4 | |
| Prefoldin mediated transfer of substrate to CCT/TriC | 21.21 | 1.74 × 10−5 | |
| Post-translational protein modification | 2.61 | 1.89 × 10−6 | |
| UCH proteinases | 11.93 | 1.04 × 10−7 | |
| Deubiquitination | 5.08 | 1.00 × 10−5 | |
|
|
| ||
| The citric acid (TCA) cycle and respiratory electron transport | 8.27 | 1.08 × 10−7 | |
| Pyruvate metabolism and citric acid (TCA) cycle | 8.84 | 4.29 × 10−3 | |
| Pyruvate metabolism | 12.72 | 4.76 × 10−3 | |
| Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins | 7.76 | 2.13 × 10−5 | |
| Respiratory electron transport | 7.63 | 2.42 × 10−4 | |
| Metabolism of amino acids and derivatives | 6.8 | 4.19 × 10−11 | |
| Histidine, lysine, phenylalanine, tyrosine, proline and tryptophan catabolism | 10.37 | 2.29 × 10−3 | |
| Glyoxylate metabolism and glycine degradation | 12.31 | 5.25 × 10−3 | |
| Gluconeogenesis | 11.57 | 6.32 × 10−3 | |
|
|
| ||
| Cellular responses to stress | 6.31 | 1.04 × 10−10 | |
| Cellular response to hypoxia | 12.72 | 7.28 × 10−7 | |
| Oxygen-dependent proline hydroxylation of HIF-1α | 14.46 | 3.37 × 10−7 | |
| Cellular response to heat stress | 13.16 | 5.52 × 10−8 | |
| HSF1 activation | 39.77 | 1.15 × 10−5 | |
| HSF1-dependent transactivation | 31.81 | 9.12 × 10−8 | |
| Attenuation phase | 34.08 | 1.98 × 10−5 | |
| Regulation of HSF1-mediated heat shock response | 7.12 | 9.56 × 10−3 | |
| HSP90 chaperone cycle for steroid hormone receptors (SHR) | 13.63 | 6.36 × 10−6 | |
|
|
| ||
|
|
| ||
|
|
| ||
|
|
| ||
| Striated muscle contraction | 23.86 | 8.26 × 10−8 | |
| Smooth muscle contraction | 10.91 | 7.55 × 10−3 | |
|
|
| ||
| CREB phosphorylation through the activation of CaMKII | 19.09 | 5.28 × 10−3 |
Upregulated proteins belonging to the GO category “contractile fibers” in the collagen (COL) and placebo (PLA) groups.
| UniProt | Gene Name | Protein Description | Fold Change | FDR |
|---|---|---|---|---|
| Only upregulated in COL after 12 weeks of training | ||||
| P35609 | ACTN2 | Alpha-actinin-2 | 1.57 | 0.006 |
| Q9GZV1 | ANKR2 | Ankyrin repeat domain-containing protein 2 | 1.62 | 0.025 |
| O95817 | BAG3 | BAG family molecular chaperone regulator 3 | 1.87 | 0.004 |
| O00499 | BIN1 | Myc box-dependent-interacting protein 1 | 1.79 | 0.000 |
| P17661; P07197 | DESM | Desmin | 1.70 | 0.002 |
| O00757 | F16P2 | Fructose-1,6-bisphosphatase isozyme 2 | 1.51 | 0.020 |
| Q96A32 | MLRS | Myosin regulatory light chain 2, skeletal muscle isoform | 1.70 | 0.007 |
| P13535 | MYH8 | Myosin-8 | 2.55 | 0.047 |
| P05976; Q15111 | MYL1 | Myosin light chain 1/3, skeletal muscle isoform | 1.61 | 0.009 |
| Q9UBF9 | MYOTI | Myotilin | 1.51 | 0.008 |
| O14974 | MYPT1 | Protein phosphatase 1 regulatory subunit 12A | 1.54 | 0.021 |
| Q53GG5 | PDLI3 | PDZ and LIM domain protein 3 | 1.93 | 0.000 |
| P60900 | PSA6 | Proteasome subunit alpha type-6 | 1.56 | 0.017 |
| Q9UHP9 | SMPX | Small muscular protein | 2.03 | 0.000 |
| A8MU46 | SMTL1 | Smoothelin-like protein 1 | 2.05 | 0.003 |
| P23327 | SRCH | Sarcoplasmic reticulum histidine-rich calcium-binding protein | 1.96 | 0.003 |
| Q9H7C4 | SYNCI | Syncoilin | 1.51 | 0.026 |
| O15061 | SYNEM | Synemin | 1.57 | 0.003 |
| Q8N3V7 | SYNPO | Synaptopodin | 1.82 | 0.016 |
| Q9NZQ9 | TMOD4 | Tropomodulin-4 | 1.92 | 0.002 |
| P02585; P27482 | TNNC2 | Troponin C, skeletal muscle | 1.98 | 0.002 |
| P48788 | TNNI2 | Troponin I, fast skeletal muscle | 1.98 | 0.006 |
| P07951; O75330 | TPM2 | Tropomyosin beta chain | 1.88 | 0.000 |
| P06753 | TPM3 | Tropomyosin alpha-3 chain | 2.07 | 0.004 |
| Q9BYV2 | TRI54 | Tripartite motif-containing protein 54 | 2.15 | 0.033 |
| Only upregulated in PLA group after 12 weeks of training | ||||
| P02511 | CRYAB | Alpha-crystallin B chain | 2.01 | 0.037 |
| Q6P5Q4 | LMOD2 | Leiomodin-2 | 2.80 | 0.014 |
Upregulated proteins from the intersection, collagen (COL), and placebo (PLA) groups belonging to collagen proteins or collagen-associated proteins.
| UniProt | Gene Name | Protein Description | Fold Change (FC) | FDR | |||
|---|---|---|---|---|---|---|---|
| Collagen | Placebo | Collagen | Placebo | ||||
| Upregulated in both groups after 12 weeks | |||||||
| P12110 | CO6A2 | Collagen alpha-2(VI) chain | 2.86 | 3.17 | 0.001 | 0.000 | |
| P02751 | FINC | Fibronectin | 4.46 | 2.24 | 0.007 | 0.021 | |
| P11047 | LAMC1 | Laminin subunit gamma 1 | 1.90 | 1.71 | 0.023 | 0.022 | |
| Only upregulated in COL after 12 weeks | |||||||
| P20908 | CO5A1 | Collagen alpha-1(V) chain | 108.74 | - | 0.018 | - | |
| P39059 | COFA1 | Collagen alpha-1(XV) chain | 1.69 | - | 0.028 | - | |
| P39060 | COIA1 | Collagen alpha-1(XVIII) chain | 2.85 | - | 0.001 | - | |
| Only upregulated in PLA after 12 weeks | |||||||
| P51884 | LUM | Lumican | - | 1.59 | - | 0.001 | |